Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - CytomX Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: cancer therapeutics - CytomX Therapeutics

Alternative Names: 4-1BB agonistic monoclonal antibodies - CytomX Therapeutics; CD137 agonistic monoclonal antibodies - CytomX Therapeutics; Pb-IFN-α2b; Pb-IFN-α2b - CytomX Therapeutics

Latest Information Update: 30 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Class Antineoplastics; Cytokines; Immunotherapies; Interferons; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Interferon alpha-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Apr 2022 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trials in cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 29 Jun 2021 Preclinical trials in Cancer in USA (Parenteral) before June 2021
  • 29 Jun 2021 Pharmacodynamics data from preclinical trial in Cancer released by CytomX Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top